Cargando…
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Tumours require a vascular supply to grow and can achieve this via the expression of pro-angiogenic growth factors, including members of the vascular endothelial growth factor (VEGF) family of ligands. Since one or more of the VEGF ligand family is overexpressed in most solid cancers, there was grea...
Autores principales: | Vasudev, Naveen S., Reynolds, Andrew R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061466/ https://www.ncbi.nlm.nih.gov/pubmed/24482243 http://dx.doi.org/10.1007/s10456-014-9420-y |
Ejemplares similares
-
Erratum to: Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
por: Vasudev, Naveen S., et al.
Publicado: (2014) -
Direct or indirect endothelial damage? An unresolved question
por: Basta, Giuseppina
Publicado: (2021) -
Emergence agitation: current knowledge and unresolved questions
por: Lee, Seok-Jin, et al.
Publicado: (2020) -
Endometrial Stem Cell Markers: Current Concepts and Unresolved Questions
por: Tempest, Nicola, et al.
Publicado: (2018) -
Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions
por: Syro, Luis V., et al.
Publicado: (2018)